
Infliximab Intravenous (IV) Solution
Form: Intravenous (IV) Solution
Strength: 100 mg/20 mL, 100 mg/10 mL
Reference Brands: Remicade (US & EU)
Category: Arthritis
Infliximab IV solution is approved in the EU and US for treating rheumatoid arthritis and other autoimmune diseases. In the EU, brands like Remicade are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on extensive clinical data, biosimilarity, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for infliximab IV formulations, ensuring adherence to European and American standards for safe, effective biologic therapy, helping you navigate complex regulatory frameworks seamlessly.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Pegloticase injecatble
Strength: 8 mg/1.2 mL vial
Form: Injectable (IV solution)
Reference Brands: Krystexxa (US)
View Details Get EnquiryColchicine tablest
Strength: 0.6 mg
Form: Tablet
Reference Brands: Colcrys(US)
View Details Get EnquiryFebuxostat tablets
Strength: 40 mg, 80 mg
Form: Oral Tablets
Reference Brands: Uloric(EU & US)
View Details Get EnquiryAllopurinol tablets
Strength: 100 mg, 300 mg
Form: Oral Tablets
Reference Brands: Aloprim(US & EU)
View Details Get Enquiry